Table 1.
PACT clinical cell products and their corresponding treatment indications
| Cell product | Treatment indication or objective |
|---|---|
| Cardiac stem/progenitor cells | • Cardiac regeneration in acute myocardial infarction |
| Mesenchymal stem cells (MSCs)* | • Repair cardiac damage following myocardial infarction• Sickle cell disease• Acute lung injury |
| Autologous bone marrow mononuclear cells* | • Cardiac repair left ventricular assist device (LVAD) placement• Stroke• Left ventricular function following acute myocardial infarction• Treatment of traumatic brain injury |
| T‐regulatory cells (umbilical cord blood and peripheral blood—derived) | • Prevent graft‐versus‐host disease (GVHD)• Enhance engraftment |
| Multivirus‐specific cytotoxic T lymphocytes (peripheral blood and bone marrow‐derived) | • Prevent and treat viral infections (CMV, EBV, adenovirus)• Treatment of refractory posttransplant lymphoproliferative disease |
| Dendritic cells pulsed with inactivated HIV‐1 infected apoptotic cells | • Therapeutic vaccine for HIV‐1 infected patients |
| Antisense oligonucleotide‐treated dendritic cells | • Preserve residual beta cell mass in type 1 diabetes |
| Allogeneic natural killer cells | • Gain durable remission• Hematopoietic stem cell transplant preparative regimen |
| CD133+ progenitor cells (peripheral blood and bone marrow‐derived) | • Critical limb ischemia• Chronic ischemic cardiomyopathy |
| Peripheral blood‐derived inducible T‐reg cells | • Prevention and treatment of GVHD |
| Gene modified CD34+ cells | • Treatment of SCID‐X1 |
*Multiple applications are grouped by cell product.